Schubert & Co’s ImmunityBio IBRX Stock Holding History

Schubert & Co’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$10	–	728
2023 Q1	$10	Sell	5 -6	-55%	-$19	﹤0.01%	1666
2022 Q4	$56	Buy	+11	New	+$60	﹤0.01%	1609
2022 Q2	–	Sell	-8	Closed	–	–	1516
2022 Q1	$0	Buy	8 +5	+167%	+$31	﹤0.01%	1190
2021 Q4	$0	Buy	+3	New	+$23	﹤0.01%	1133

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Schubert & Co's IBRX Position: Q2 2023 in Review

Schubert & Co sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 5 shares — an estimated $10 sold.

Schubert & Co first reported a position in IBRX in Q4 2021 and held it in 4 quarters. The position peaked at $56 in Q4 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Schubert & Co reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 5 ImmunityBio shares in Q2 2023, an estimated $10.
Schubert & Co first reported a position in ImmunityBio in Q4 2021 and held it in 4 quarters.
Schubert & Co's ImmunityBio position peaked at $56 in Q4 2022.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.